For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The Wellcome Collection in London to talk about the UK biotech he co-founded, its strategy and bringing innovation to life through Blueberry’s nanomedicine approach.
Gene therapy and market access: the pharmaphorum podcast
AMR research and Matoke Pharma: the pharmaphorum podcast
GSK and digital disruption: the pharmaphorum podcast
Ipsen on neurotoxin research: the pharmaphorum podcast
Successful medical marketing teams: the pharmaphorum podcast
Commercialising orphan drugs: the pharmaphorum podcast
The future biosimilar landscape: the pharmaphorum podcast
Nimble consumer healthcare innovation: the pharmaphorum podcast
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths